PR99413

SAN FRANCISCO, Jan. 10, 2023 /PRNewswire=KYODO JBN/ --

Complete Genomics Inc (https://completegenomics.mgiamericas.com/), a subsidiary

of MGI Tech Co., Ltd. ("MGI"), today unveiled its full sequencing platforms at

Biotech Showcase during JP Morgan Healthcare Conference Week 2023. Rade

Drmanac, PhD, Chief Scientific Officer, announced "free three-month trial"

program and "reagent rental leasing" program, giving customers the opportunity

to experience the quality and reliability of its products before purchasing

them.

Founded in 2006 in Silicon Valley, Complete Genomics is a leading innovator of

high-throughput sequencing technologies, with end-to-end multi-omics platforms

including genetic sequencing and laboratory automation. Complete Genomics

developed its own patented DNA nanoball-based sequencing technology DNBSEQ™.

Featuring DNBs (DNA NanoBalls) with high signal density on patterned nanoarray

to greatly improve detection accuracy and efficiency, DNBSEQ boasts high

performance in applications such as WGS (whole-genome sequencing)/WES

(whole-exome sequencing) with low duplication rates and higher Indel

accuracies. This innovative technology eliminates index hopping and clonal

errors during the sequencing step of the workflow, facilitating greater

accuracy and flexibility.

Dr. Drmanac introduced a series of DNBSEQ technology-based sequencing platforms

that are available in the US market, including DNBSEQ-G400C*, a day-to-day,

medium throughput benchtop sequencer that can flexibly support a variety of

different sequencing modes, which was launched in the US last year.

As Complete Genomics enters 2023, it offers more innovative sequencing

platforms for US customers to power their genomics research and related

efforts. These offerings range from low to ultra-high throughput to meet

diverse needs, which include:

DNBSEQ-E25* as a portable sequencer with a very low throughput of up to 7.5 Gb

daily. Easy setup makes it ready to run in ten minutes, coupled with fast

turnaround time of ~ 20 hours from DNA samples to FASTQ data. This product will

be launched in Q2 2023.

DNBSEQ-T7* as an ultra-high throughput sequencer that offers one of the highest

flexibilities among sequencers in the market with four independent flow cells

running at any time. With an output of 1-7 Tb of high-quality data per day, it

can achieve over 20,000 of 30X WGS in less than one year. This highly efficient

and cost-effective sequencer is available now.

DNBSEQ-T10x4* as one of the world's largest and highest throughput next

generation sequencers available with a robotic arm and data output of up to 18

Tb daily. This product is available now.

Complete Genomics offers products from lab automation to data analysis/storage

tools covering the full NGS workflow to accelerate scientific findings and

breakthroughs in genomic medicine.

Based on DNBSEQ technology, which makes sequencing much more accurate, flexible

and affordable, Complete Genomics has generated great interest within the

scientific community and formed partnerships with various life science

companies and scientific institutions. In August 2022, its DNBSEQ-G400C

sequencer was released in the US with immediate adoption in dozens of customer

labs and partnerships with various life science companies, including Sentieon,

a developer of highly accurate and optimized algorithms for bioinformatics

applications. "Complete Genomics provides high-quality, accurate and accessible

products, giving the genomics community a 'Power of Choice' in sequencing. We

look forward to providing even more innovative platforms through future

partnerships to meet the diverse needs of the life science industry," said Jun

Ye, CEO of Sentieon.

"In the past years, we are winning the recognition of more and more US

customers through advanced patented technologies, high-quality products, and

professional services," said Dr. Drmanac. "We do not just sell products; we

enable partners. Through understanding the latest genomics needs of the US

market, providing early product access, and fostering collaborations with local

partners, we seek to further advance life science and provide customers around

the globe with 'the right for another choice.'"

Through Complete Genomics new "free three-month trial" program, participating

institutions will gain access to selected sequencing platforms. Complete

Genomics is offering a money back guarantee if customers are not completely

satisfied with their instrument purchase. To further support the financial

commitment, Complete Genomics offers qualified professionals the opportunity to

apply for the reagent rental leasing program. For further information, please

reach out to sales@completegenomics.com.

Complete Genomics takes data security seriously. All DNBSEQ sequencing

platforms can work as a stand-alone system from sample to result without any

internet connection, so there is no risk of data breaches. Customers will have

100% control of their data security.

About Complete Genomics

Complete Genomics Inc, a subsidiary of MGI Tech Co., Ltd., is a global life

science company offering lab automation and a comprehensive high throughput

sequencing product portfolio. Founded in 2006 and currently located in San

Jose, California, Complete Genomics maintains a demo lab and full supply center

with all of the reagents, lab automation equipment and sequencers locally

stored for customers. Complete Genomics released its first next-generation

sequencing system, the DNBSEQ-G400C* platform in the US, in August 2022. For

all sequencer specifications, please visit the Complete Genomics website.

*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and

sequencers for use with such reagents, are not available in Germany, Spain, UK,

Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal,

Austria, and Romania. Unless otherwise informed, StandardMPS sequencing

reagents, and sequencers for use with such reagents are not available in Hong

Kong.

CONTACTS

Shani Lewis

Assistant Vice President, Media

LaVoieHealthScience

(617) 865-5554

slewis@lavoiehealthscience.com

Dada Zhang

Senior Public Relationship Manager

Complete Genomics

zhangling8@mgi-tech.com

SOURCE: Complete Genomics